The diagnosis and management of Systemic Lupus Erythematosus (SLE) rely heavily on precise laboratory markers. Among these, anti-dsDNA antibody immunoassays remain central for confirming the disease and monitoring clinical flares. A recent comparative study evaluated three common platforms: radioimmunoassay (RIA), chemiluminescence enzyme immunoassay (CLEIA), and fluorescence enzyme immunoassay (FEIA). While all three demonstrate comparable diagnostic accuracy, their sensitivity and association with specific organ involvement vary.

Furthermore, the results indicate that these systems show moderate to substantial correlation. However, differences in detection technology lead to unique reactivity patterns in certain patients. For instance, the fully automated CLEIA system exhibits high sensitivity. This feature makes it particularly effective for reflecting overall disease activity. Consequently, clinicians might prefer this platform when they need a sensitive tool for routine monitoring.

Clinical Impact of Anti-dsDNA Antibody Immunoassays on Organ Involvement

Individual organ manifestations also seem to correlate with specific testing methods. The study found that nephritis correlates significantly with CLEIA titers. In contrast, arthritis shows a stronger association with RIA results. Therefore, the choice of a specific assay could influence clinical decision-making. Physicians should consider the patient's primary symptoms when selecting a testing platform.

Additionally, standardizing these results remains a challenge in rheumatology. The 2019 EULAR/ACR classification criteria emphasize that these assays must maintain a specificity of at least 90%. Because each platform has its strengths, some experts suggest using a high-sensitivity screening assay followed by a high-specificity confirmatory test. This approach ensures both early detection and diagnostic precision.

FAQs

Which anti-dsDNA immunoassay is best for monitoring disease activity?

While all assays are comparable, the fully automated CLEIA system demonstrated higher sensitivity in reflecting overall SLE disease activity in recent studies.

Are certain assays better for predicting lupus nephritis?

Yes, research indicates that CLEIA titers and positivity rates show a significant association with nephritis, whereas RIA may be more reflective of arthritis.

Can I use different assays interchangeably for the same patient?

No, clinical guidelines suggest using the same laboratory and method for serial monitoring. Switching platforms can lead to inconsistent titers due to different detection systems.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Uto K et al. Clinical performance of three anti-dsDNA antibody immunoassays in systemic lupus erythematosus. Mod Rheumatol. 2026 Feb 27. doi: undefined. PMID: 41757496.

2. Liu X et al. Comparative evaluation of three anti-dsDNA antibody detection methods in systemic lupus erythematosus. PMC. 2025 Apr 10. doi: 10.1186/s12891-025-08145-y.

3. Ghirardello A et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol. 2011;29(1):50-56.